Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- NanoCarrier Obtains Substance Patent for Its “pH-Responsive Micelle” in China
September 19, 2011
- Sales of Ethical Drugs Up 0.1% in July: Crecon & Research Consulting
September 19, 2011
- Sandoz to Use Its Unique Anticancer Drug Container for More Anticancer Drugs
September 19, 2011
- Nichi-Iko, Pfizer Apply for Add’l Indication for Generic Cisplatin Using Data from Public Domain
September 19, 2011
- M3 to Start “Web Lecture” Service for Drug Makers
September 19, 2011
- All-case PMS Completed for Colorectal Cancer Treatment Erbitux: Merck Serono
September 19, 2011
- Nippon Shinyaku Discloses Details on Halcion-Laced Liquor Incident
September 19, 2011
- Novartis Applies for Tobramycin for Cystic Fibrosis of Pancreas
September 19, 2011
- BMKK Files for Add’l Indications for 2 Drugs Based on Data in Public Domain
September 19, 2011
- Janssen Adds Precautions for Concerta for Patients Over 18
September 19, 2011
- Takeda to Initiate Domestic PIII Trial for Once-weekly DPP-4 Inhibitor
September 19, 2011
- Astellas, UMN Pharma Complete Cell Culture–based Flu Vaccine Inoculation of Subjects in PI/PII Trials
September 16, 2011
- OncoTherapy Completes Patient Enrolment for PII Trial of Angiogenesis Inhibitor
September 16, 2011
- Everolimus Obtains EU Approval for SEGA: Novartis
September 16, 2011
- Ono Pharmaceutical Licenses Ca Receptor Agonist from US Company
September 16, 2011
- Ono Licenses in Ion Channel Inhibitor Ivabradine from Servier
September 15, 2011
- Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future
September 15, 2011
- Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
- JCR Revises Half-, Full-Year Business Forecasts for FY Ending March 2012
September 14, 2011
- DSP to End Sales of Melbin
September 14, 2011
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…